New Results
Collagen XVIII promotes breast cancer through EGFR/ErbB signaling and its ablation improves the efficacy of ErbB-targeting inhibitors
Raman Devarajan, Hellevi Peltoketo, Valerio Izzi, Heli Ruotsalainen, Saila Kauppila, Marja-Riitta Väisänen, Gunilla Rask, Guillermo Martínez-Nieto, Sanna-Maria Karppinen, Timo Väisänen, Inderjeet Kaur, Jussi Koivunen, Takako Sasaki, Robert Winqvist, Fredrik Wärnberg, Malin Sund, Taina Pihlajaniemi, Ritva Heljasvaara
doi: https://doi.org/10.1101/2022.01.10.474416
Raman Devarajan
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
2Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, University of Oulu; Oulu, Finland
3Biocenter Oulu, University of Oulu; Oulu, Finland
Hellevi Peltoketo
2Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, University of Oulu; Oulu, Finland
3Biocenter Oulu, University of Oulu; Oulu, Finland
Valerio Izzi
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
4Research Unit of Biomedicine, University of Oulu; Oulu, Finland
5Finnish Cancer Research Institute, Helsinki; Finland
Heli Ruotsalainen
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
Saila Kauppila
6Department of Pathology, Oulu University Hospital and University of Oulu; Oulu, Finland
7Northern Finland Laboratory Centre, NordLab; Oulu, Finland
Marja-Riitta Väisänen
8Department of Pathology, Kainuu Central Hospital, Kajaani; Finland
Gunilla Rask
9Department of Medical Biosciences/Pathology, Umeå University; Umeå, Sweden
Guillermo Martínez-Nieto
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
Sanna-Maria Karppinen
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
Timo Väisänen
6Department of Pathology, Oulu University Hospital and University of Oulu; Oulu, Finland
Inderjeet Kaur
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
Jussi Koivunen
10Department of Medical Oncology and Radiotherapy and Medical Research Center, Oulu University Hospital and University of Oulu; Oulu, Finland
Takako Sasaki
11Deparment of Biochemistry, Faculty of Medicine, Oita University; Oita, Japan
Robert Winqvist
2Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, University of Oulu; Oulu, Finland
3Biocenter Oulu, University of Oulu; Oulu, Finland
7Northern Finland Laboratory Centre, NordLab; Oulu, Finland
Fredrik Wärnberg
12Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg; Gothenburg, Sweden
Malin Sund
13Department of Surgery and Perioperative Sciences/Surgery, Umeå University; Umeå, Sweden
14Department of Surgery, University of Helsinki and Helsinki University Hospital; Helsinki, Finland
Taina Pihlajaniemi
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
Ritva Heljasvaara
1Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine, University of Oulu; Oulu, Finland
Posted January 11, 2022.
Collagen XVIII promotes breast cancer through EGFR/ErbB signaling and its ablation improves the efficacy of ErbB-targeting inhibitors
Raman Devarajan, Hellevi Peltoketo, Valerio Izzi, Heli Ruotsalainen, Saila Kauppila, Marja-Riitta Väisänen, Gunilla Rask, Guillermo Martínez-Nieto, Sanna-Maria Karppinen, Timo Väisänen, Inderjeet Kaur, Jussi Koivunen, Takako Sasaki, Robert Winqvist, Fredrik Wärnberg, Malin Sund, Taina Pihlajaniemi, Ritva Heljasvaara
bioRxiv 2022.01.10.474416; doi: https://doi.org/10.1101/2022.01.10.474416
Collagen XVIII promotes breast cancer through EGFR/ErbB signaling and its ablation improves the efficacy of ErbB-targeting inhibitors
Raman Devarajan, Hellevi Peltoketo, Valerio Izzi, Heli Ruotsalainen, Saila Kauppila, Marja-Riitta Väisänen, Gunilla Rask, Guillermo Martínez-Nieto, Sanna-Maria Karppinen, Timo Väisänen, Inderjeet Kaur, Jussi Koivunen, Takako Sasaki, Robert Winqvist, Fredrik Wärnberg, Malin Sund, Taina Pihlajaniemi, Ritva Heljasvaara
bioRxiv 2022.01.10.474416; doi: https://doi.org/10.1101/2022.01.10.474416
Subject Area
Subject Areas
- Biochemistry (11736)
- Bioengineering (8746)
- Bioinformatics (29186)
- Biophysics (14964)
- Cancer Biology (12084)
- Cell Biology (17401)
- Clinical Trials (138)
- Developmental Biology (9418)
- Ecology (14176)
- Epidemiology (2067)
- Evolutionary Biology (18299)
- Genetics (12235)
- Genomics (16793)
- Immunology (11863)
- Microbiology (28066)
- Molecular Biology (11580)
- Neuroscience (60925)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4956)
- Plant Biology (10422)
- Synthetic Biology (2883)
- Systems Biology (7338)
- Zoology (1650)